Neko Health: The $7 Billion Bet on Preventive Care as a Consumer Habit

1. Introduction: Why Neko Health Matters

Neko Health matters because it is attempting something that almost no one in healthcare has pulled off: turning a medical service into a consumer habit.

In July 2026, the Stockholm-based company raised $700 million in Series C funding at a valuation of nearly $7 billion, a fourfold increase from its $1.7 billion valuation just 18 months earlier. The investor list is extraordinary: Lightspeed Venture Partners, General Catalyst, Atomico, and a constellation of celebrity backers including Mark Zuckerberg, Maria Sharapova, Thierry Henry, and Claudia Schiffer.

The company was founded in 2018 by Daniel Ek, the co-founder of Spotify, and Hjalmar Nilsonne, who serves as CEO. Their thesis was simple: healthcare is reactive when it should be preventive, and the technology to make preventive care a consumer product did not yet exist. So they built it.

Eight years later, Neko has completed over 100,000 full-body preventive health scans. 350,000 people are on the waitlist. And 75% of customers book and prepay their next annual scan before leaving the clinic, a retention rate that would be exceptional in any industry, let alone healthcare.

But the $7 billion question is not whether Neko's product works. It does. The question is whether a model proven in Stockholm and London can survive contact with the American healthcare market.

2. The Path So Far

Neko's journey has been deliberate and capital-intensive.

The company spent its first five years in development, building proprietary hardware and software from scratch. Unlike most health-tech startups that layer software onto existing medical infrastructure, Neko designed its own devices. High-resolution 2D and 3D cameras for full-body skin mapping. Cardiovascular sensors. Blood analysis systems. All engineered to work as one integrated system, producing millions of data points that are analysed by AI and reviewed by a doctor, all within a single 60-minute visit.

The first clinics opened in Stockholm and London in 2023, backed by a $65 million funding round. By early 2025, the company had completed 10,000 scans and attracted 100,000 people to its waitlist. A $260 million Series B led by Lightspeed Venture Partners followed, valuing the company at $1.7 billion.

The next 18 months transformed the business. Neko expanded from two clinics to eight across the UK and Sweden. Scan volume grew from 10,000 to over 100,000, an 11-fold increase in throughput. Multiple device generations were released: Derma-2 for skin imaging, Echo-2 for cardiovascular assessment, Spectrum-2 for body composition. The waitlist swelled to 350,000.

And crucially, retention held. At 10,000 scans, 80% of customers rebooked. At 100,000 scans, 75% still do. A five-percentage-point drop at ten times the volume is a signal of genuine product-market fit, not early-adopter enthusiasm.

3. Where Neko Sits on the Growth Journey

Neko is in what we would call an early industrialisation phase. The technology is proven. The business model is validated in two European markets. The capital is abundant. The brand is strong.

But the operational base is still small: eight clinics, two countries, one continent. The company is now attempting a transition that has broken many promising ventures before it, moving from a tightly controlled proof-of-concept in friendly markets to scaled operations in hostile territory.

The US is not a larger Sweden. It has higher physician and real estate costs, a more complex regulatory environment, a more litigious medical culture, and established competitors that have been operating there for years. Prenuvo has completed over 170,000 whole-body MRI scans. Function Health and Ezra offer MRI access through 170+ partner locations. These are not small players.

Neko's first US clinic opens in New York this year. It is not just a launch. It is a test of whether the model translates.

4. Why Neko Has Reached This Point

Three structural advantages explain Neko's trajectory to date.

The product experience is genuinely different. Most medical experiences are designed around the provider: waiting rooms, fragmented tests, delayed results, rushed consultations. Neko inverted that. One hour. One visit. Millions of data points. AI analysis in minutes. Same-day doctor review. No radiation. All for the price of a premium hotel room. The "Apple of healthcare" label is not just marketing. The 75% rebooking rate is proof that the experience delivers on its promise.

Vertical integration creates a defensible moat. Neko builds its own hardware, writes its own software, operates its own clinics, and employs its own clinicians. Competitors can replicate individual layers: Prenuvo does MRI scans, Function does lab tests, but no competitor replicates the full integrated stack. This makes Neko difficult to copy and even more difficult to displace once a customer is inside the system. Each annual scan adds data that deepens the relationship and raises switching costs.

The Ek effect is real. Investors are not betting on a medical device company. They are betting that Daniel Ek, who turned music streaming from a utility into a daily consumer habit for hundreds of millions of people, can apply the same playbook to preventive health. The celebrity investor roster signals a consumer-brand ambition, not a healthcare-IT one. The valuation reflects that narrative premium.

5. Four Challenges for the Next Phase

For all its strengths, Neko faces four structural challenges that will define whether the $7 billion valuation proves prescient or premature.

Challenge 1: Physical expansion cannot match valuation expectations. Each Neko clinic requires real estate acquisition, local regulatory approvals, proprietary device manufacturing, and hiring clinical staff. These are multi-year, multi-million-dollar projects. You cannot push a clinic into a new market with a software update. The valuation implies a growth trajectory- hundreds of clinics, millions of scans- that may simply not be physically achievable at the speed the market expects. Capital abundance does not solve construction timelines or clinical hiring pipelines.

Challenge 2: The walled garden limits the velocity of distribution. Neko's owned-clinic model gives total control over experience and data, and that is a genuine competitive advantage. But it also means Neko cannot grow through hospital partnerships, insurer networks, employer wellness programmes, or franchise models. Every unit of growth requires a new physical clinic, each taking 12-18 months to bring online. Prenuvo faces the same constraint, but the combined Function/Ezra entity uses a partner-location model that leverages existing MRI infrastructure across 170+ locations. That model scales faster, even if it sacrifices some control over experience. Neko needs at least one partnership-based growth channel to increase distribution velocity without a proportional increase in capital expenditure.

Challenge 3: The US is not a larger Sweden. Everything Neko has proven- £299 pricing, 75% retention, consumer enthusiasm- was proven in markets with socialised healthcare systems, lower clinical salaries, and lighter regulatory burdens. US physician costs alone could fundamentally alter the unit economics. US consumers have different expectations, more choices, and a more transactional relationship with healthcare providers. And US competitors are not standing still. The assumption that the European model transfers intact is the single biggest risk in the investment case.

Challenge 4: Medical credibility has not yet been built. The mainstream medical community is sceptical of full-body preventive scanning. The concern is legitimate: false positives cause anxiety and trigger unnecessary follow-up procedures that burden the healthcare system. The Alex Tew story, a Calm founder whose Neko scan detected a malignant mole, is compelling, but it is one anecdote. Neko has 100,000+ clinical data scans. It should publish outcomes: detection rates, false-positive rates, downstream procedure rates. Converting medical professionals from sceptics into referral sources requires evidence, not branding. Without that conversion, Neko's addressable market is limited to health-conscious consumers willing to pay out of pocket, a large market, but perhaps not a $7 billion one.

6. A Patient Growth Agenda

Neko does not need to move faster. It needs to move more carefully. Five priorities for the next phase:

Prove US unit economics before scaling. The NYC clinic should be treated as an experiment, not a launch. Measure everything against European benchmarks. Adjust pricing or the operating model based on data, not assumptions. Open clinic two only when the model is confirmed. A slow, deliberate US entry preserves the $7 billion valuation. A fast, expensive failure destroys it.

Build a second growth engine. Owned clinics are the core, but Neko needs at least one partnership-based distribution channel. Employer wellness programmes are the obvious starting point, a natural fit for a preventive-health product, and a way to reach customers through their employers rather than direct-to-consumer marketing alone.

Publish clinical evidence. The 100,000-scan dataset is a strategic asset that Neko is underusing. Outcomes data builds medical credibility, opens referral pathways, and differentiates Neko from competitors who cannot match the dataset size. This is not a marketing exercise. It is a strategic necessity.

Build the organisation for multi-market operations. European clinics were built one at a time by a close-knit team. US expansion requires a different organisational design: local clinical leadership, US-specific regulatory expertise, independent supply chains, and a management layer that can operate without daily founder involvement. The organisation must scale ahead of the clinic count, not behind it.

Respect the difference between music and medicine. Daniel Ek's expertise in consumer habits is Neko's greatest asset. But healthcare is not music streaming. A false positive is not a song you skip. The instinct to move fast and iterate, so powerful in consumer tech, must be tempered by clinical reality. Mistakes in healthcare have consequences. The Spotify playbook works for the consumer experience layer. It does not work for the clinical safety layer.

7. Implications for the European Health-Tech Ecosystem

Neko Health is a test case with significance beyond one company.

If the US expansion succeeds, if the European model translates, if retention holds, if unit economics works at American cost levels, it validates the thesis that European health-tech can produce globally significant consumer brands. It demonstrates that vertical integration in healthcare produces both better patient experiences and defensible economics. And it proves that preventive health is a viable consumer category, not just a medical one.

If it stumbles, the lesson will be more sobering: that healthcare markets are more local, more regulated, and more resistant to consumer-tech playbooks than investors hope. The $7 billion question is not whether Neko's technology works. It works. The question is whether the model that works in Stockholm and London works in New York, and whether it can scale to the hundreds of clinics the valuation demands.

New York will answer that question. The rest of the European health-tech ecosystem should watch closely.